Ability of Adeno-Associated Virus Serotype 8-Mediated Hepatic Expression of Acid α-Glucosidase to Correct the Biochemical and Motor Function Deficits of Presymptomatic and Symptomatic Pompe Mice
- 1 June 2008
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 19 (6), 609-621
- https://doi.org/10.1089/hum.2008.010
Abstract
The availability of a murine model of Pompe disease has enabled an evaluation of the relative merits of various therapeutic paradigms, including gene therapy. We report here that administration of a recombinant adeno-associated virus serotype 8 (AAV8) vector (AAV8/DC190-GAA) encoding human acid α-glucosidase (GAA) into presymptomatic Pompe mice resulted in nearly complete correction of the lysosomal storage of glycogen in all the affected muscles. A relatively high dose of AAV8/DC190-GAA was necessary to attain a threshold level of GAA for inducing immunotolerance to the expressed enzyme and for correction of muscle function, coordination, and strength. Administration of AAV8/DC190-GAA into older Pompe mice with overt disease manifestations was also effective at correcting the lysosomal storage abnormality. However, these older mice exhibited only marginal improvements in motor function and no improvement in muscle strength. Examination of histologic sections showed evidence of skeletal muscle degeneration and fibrosis in aged Pompe mice whose symptoms were abated or rescued by early but not late treatment with AAV8/DC190-GAA. These results suggest that AAV8-mediated hepatic expression of GAA was effective at addressing the biochemical and functional deficits in Pompe mice. However, early therapeutic intervention is required to maintain significant muscle function and should be an important consideration in the management and treatment of Pompe disease.Keywords
This publication has 40 references indexed in Scilit:
- Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe diseaseMolecular Genetics and Metabolism, 2007
- Autophagy and Mistargeting of Therapeutic Enzyme in Skeletal Muscle in Pompe DiseaseMolecular Therapy, 2006
- Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapyBlood, 2006
- New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapyHuman Genetics, 2006
- Evasion of Immune Responses to Introduced Human Acid α-Glucosidase by Liver-Restricted Expression in Glycogen Storage Disease Type IIMolecular Therapy, 2005
- AAV8-Mediated Hepatic Expression of Acid Sphingomyelinase Corrects the Metabolic Defect in the Visceral Organs of a Mouse Model of Niemann–Pick DiseaseMolecular Therapy, 2005
- Impact of Humoral Immune Response on Distribution and Efficacy of Recombinant Adeno-Associated Virus-Derived Acid α-Glucosidase in a Model of Glycogen Storage Disease Type IIHuman Gene Therapy, 2005
- Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapyProceedings of the National Academy of Sciences, 2002
- Correction of the Enzymatic and Functional Deficits in a Model of Pompe Disease Using Adeno-associated Virus VectorsMolecular Therapy, 2002
- Human Acid -Glucosidase from Rabbit Milk Has Therapeutic Effect in Mice with Glycogen Storage Disease Type IIHuman Molecular Genetics, 1999